22
Feb
2021

Alta Reloads, AstraZeneca Loses Cancer Indication, & Sanofi/GSK Vaccine Reboots

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Mental Health: A New Frontier for Biotech
J&J Vaccine OK’d, Morphic Nails Integrin Target, & AZ Grabs $1B for Moderna Shares
Pfizer/BioNTech Ace Real-World Test, J&J Faces FDA Scrutiny, & Merck Pays Up
Biotech as a Beacon for Youth